<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; line</title>
	<atom:link href="http://www.tapanray.in/tag/line/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Should ‘Pharma Marketing’ Be In The Line of Fire?</title>
		<link>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-pharma-marketing-be-in-the-line-of-fire</link>
		<comments>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/#comments</comments>
		<pubDate>Sun, 26 Nov 2017 23:31:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['condo']]></category>
		<category><![CDATA[ails]]></category>
		<category><![CDATA[Allegation]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intrinsic]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[serious]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8570</guid>
		<description><![CDATA[Close to half a century ago, Peter Drucker &#8211; the Management Guru wrote: As the purpose of business is to create customers, any business enterprise has two basic functions: marketing and innovation. Drucker’s concept is so fundamental in nature that it will possibly never change, ever. That innovation &#8230; <a href="http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-pharma-marketing-be-in-the-line-of-fire/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pioglitazone Conundrum: Should The Drug Regulator Step Over The Line?</title>
		<link>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line</link>
		<comments>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/#comments</comments>
		<pubDate>Mon, 08 Jul 2013 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bladder]]></category>
		<category><![CDATA[canadian]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[claim]]></category>
		<category><![CDATA[combinations]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[diabetics]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[flutter]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indudtry]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[JAPI]]></category>
		<category><![CDATA[liability]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacovigilance]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Section 26A]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Sweden]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[withdrawal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2883</guid>
		<description><![CDATA[Recent order of the Indian drug regulator to withdraw all formulations of the well known, yet controversial, anti-diabetic drug &#8211; Pioglitazone from the domestic market has created a flutter in the country, ruffling many feathers at the same time. Withdrawal &#8230; <a href="http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Finance Ministry Disallows Expenses on &#8216;Freebies&#8217; to Doctors by Pharma Companies in line with MCI Guidelines: A Possible Game Changer?</title>
		<link>http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer</link>
		<comments>http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/#comments</comments>
		<pubDate>Mon, 06 Aug 2012 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Disallows]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[Freebies]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Possible]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=56</guid>
		<description><![CDATA[Things are unfolding reasonably faster now related to the financial relationship between the pharmaceutical companies and the medical profession. All these issues are getting increasingly dragged into the public debate where government can no longer play the role of a &#8230; <a href="http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
